Wei Zhong1, Wenliang Zhang1, Qiong Li1, Guoxiang Xie2, Qian Sun3, Xiuhua Sun1, Xiaobing Tan1, Xinguo Sun1, Wei Jia2, Zhanxiang Zhou4. 1. Center for Translational Biomedical Research, University of North Carolina at Greensboro, North Carolina Research Campus, Kannapolis, NC 28081, USA. 2. University of Hawaii Cancer Center, Honolulu, HI 96813, USA. 3. Center for Translational Biomedical Research, University of North Carolina at Greensboro, North Carolina Research Campus, Kannapolis, NC 28081, USA; Department of Nutrition, University of North Carolina at Greensboro, Greensboro, NC 27412, USA. 4. Center for Translational Biomedical Research, University of North Carolina at Greensboro, North Carolina Research Campus, Kannapolis, NC 28081, USA; Department of Nutrition, University of North Carolina at Greensboro, Greensboro, NC 27412, USA. Electronic address: z_zhou@uncg.edu.
Abstract
BACKGROUND & AIMS: Effective therapies for alcoholic liver disease are currently unavailable. The present study tested the efficacy of Alda-1, a specific aldehyde dehydrogenase 2 (ALDH2) activator, in treating alcoholic liver disease. METHODS: Male C57BL/6J mice were exposed to alcohol for a time-course study on aldehyde metabolism. The specificity and efficacy of Alda-1 on activating hepatic ALDH2 and aldehyde clearance were determined by acute treatments. Then, mice were fed alcohol for 8 weeks with Alda-1 administration for the last 10 days to test the therapeutic potential of Alda-1. Lastly, H4IIEC3 cells were treated with ethanol, acetaldehyde, or 4-hydroxynonenal to define the link between aldehydes and hepatotoxicity. RESULTS: Alcohol feeding for 8 weeks induced hepatic ALDH2 dysfunction and aldehyde accumulation. One dose of Alda-1 administration elevated hepatic ALDH activity, which was blocked by the specific ALDH2 inhibitor, daidzin. Alda-1 accelerated acetaldehyde clearance after acute alcohol intoxication. Alda-1 treatment in the 8-week alcohol feeding model reversed liver damage along with reduction of hepatic aldehydes. Alda-1 re-activated transcription factors, upregulated fatty acid oxidation enzymes, and reversed steatosis. Alcohol-induced endoplasmic reticulum stress and apoptotic cell death were also attenuated by Alda-1. Acetaldehyde or 4-hydroxynonenal treatment to H4IIEC3 cells inactivated transcription factors and induced endoplasmic reticulum stress and apoptosis, while ethanol per se showed limited effects. CONCLUSIONS: Pharmacological activation of ALDH2 by Alda-1 reversed alcoholic steatosis and apoptosis through accelerating aldehyde clearance. This study indicates that ALDH2 is a promising molecular target and Alda-1 has therapeutic potential for treating alcoholic liver disease.
BACKGROUND & AIMS: Effective therapies for alcoholic liver disease are currently unavailable. The present study tested the efficacy of Alda-1, a specific aldehyde dehydrogenase 2 (ALDH2) activator, in treating alcoholic liver disease. METHODS: Male C57BL/6J mice were exposed to alcohol for a time-course study on aldehyde metabolism. The specificity and efficacy of Alda-1 on activating hepatic ALDH2 and aldehyde clearance were determined by acute treatments. Then, mice were fed alcohol for 8 weeks with Alda-1 administration for the last 10 days to test the therapeutic potential of Alda-1. Lastly, H4IIEC3 cells were treated with ethanol, acetaldehyde, or 4-hydroxynonenal to define the link between aldehydes and hepatotoxicity. RESULTS:Alcohol feeding for 8 weeks induced hepatic ALDH2 dysfunction and aldehyde accumulation. One dose of Alda-1 administration elevated hepatic ALDH activity, which was blocked by the specific ALDH2 inhibitor, daidzin. Alda-1 accelerated acetaldehyde clearance after acute alcohol intoxication. Alda-1 treatment in the 8-week alcohol feeding model reversed liver damage along with reduction of hepatic aldehydes. Alda-1 re-activated transcription factors, upregulated fatty acid oxidation enzymes, and reversed steatosis. Alcohol-induced endoplasmic reticulum stress and apoptotic cell death were also attenuated by Alda-1. Acetaldehyde or 4-hydroxynonenal treatment to H4IIEC3 cells inactivated transcription factors and induced endoplasmic reticulum stress and apoptosis, while ethanol per se showed limited effects. CONCLUSIONS: Pharmacological activation of ALDH2 by Alda-1 reversed alcoholic steatosis and apoptosis through accelerating aldehyde clearance. This study indicates that ALDH2 is a promising molecular target and Alda-1 has therapeutic potential for treating alcoholic liver disease.
Authors: K Kitagawa; T Kawamoto; N Kunugita; T Tsukiyama; K Okamoto; A Yoshida; K Nakayama; K Nakayama Journal: FEBS Lett Date: 2000-07-07 Impact factor: 4.124
Authors: Katja Breitkopf; Laura E Nagy; Juliane I Beier; Sebastian Mueller; Honglei Weng; Steven Dooley Journal: Alcohol Clin Exp Res Date: 2009-07-23 Impact factor: 3.455
Authors: David L Carbone; Jonathan A Doorn; Zachary Kiebler; Brante P Sampey; Dennis R Petersen Journal: Chem Res Toxicol Date: 2004-11 Impact factor: 3.739
Authors: Krisstonia Spruiell; Afua A Gyamfi; Susan T Yeyeodu; Ricardo M Richardson; Frank J Gonzalez; Maxwell A Gyamfi Journal: J Pharmacol Exp Ther Date: 2015-07-09 Impact factor: 4.030
Authors: Hereward J Wimborne; Kenji Takemoto; Patrick M Woster; Don C Rockey; John J Lemasters; Zhi Zhong Journal: Free Radic Biol Med Date: 2019-09-23 Impact factor: 7.376